(Q37251153)

English

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders

scientific article published on 08 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

type-1 diabetes

0 references

randomized controlled trial

1 reference

based on heuristic

inferred from title

1

object named as

Kevan C Herold

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Carla J Greenbaum

5

object named as

Carla J Greenbaum

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Stephen E Gitelman

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Mario R Ehlers

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Peter A Gottlieb

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

William Hagopian

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Karen D Boyle

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Lynette Keyes-Elstein

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sudeepta Aggarwal

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Deborah Phippard

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Peter H Sayre

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

James McNamara

12

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jeffrey A Bluestone

13

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

AbATE Study Team

14

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

8 July 2013

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

62

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

3766-3774

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

copyright license

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

30 August 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Metabolic pathways in T cell fate and function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Interleukin-1β produced in response to islet autoantigen presentation differentiates T-helper 17 cells at the expense of regulatory T-cells: Implications for the timing of tolerizing immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Individualizing calcineurin inhibitor therapy in renal transplantation--current limitations and perspectives.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Molecular antagonism and plasticity of regulatory and inflammatory T cell programs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

9 September 2017

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

14 September 2017

NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

26 June 2018

Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

26 June 2018

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

26 June 2018

Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

26 June 2018

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

3 September 2018

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

3 September 2018

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

3 December 2018

Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly-diagnosed type 1 diabetes: a longitudinal study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806618

3 December 2018

Islet cytotoxicity of interleukin 1. Influence of culture conditions and islet donor characteristics

1 reference

https://pubmed.ncbi.nlm.nih.gov/23835333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin

1 reference

https://pubmed.ncbi.nlm.nih.gov/23835333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23835333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2337/DB13-0345

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37251153&oldid=2158763514"